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1 Drug description 
Generic/Brand name/ATC code:  
Aflibercept/Zaltrap®/S01LA05 
Developer/Company:  
Regeneron Pharmaceuticals/Sanofi  
Description:  
Aflibercept/Zaltrap® (ziv-aflibercept) is a recombinant fusion protein com-
posed of Vascular Endothelial Growth Factor Receptors (VEGFR) 1 and 2 
fused to human IgG1 [1]. By binding to all VEGF-A isoforms and to placental 
growth factor aflibercept prevents these factors from stimulating angiogene-
sis which leads to reduced vascularisation of neoplasms and further to inhi-
bition of tumour growth [2]. Aflibercept is manufactured by recombinant 
DNA technology in a Chinese hamster ovary K-1 mammalian expression sys-
tem. It is available in single-use vials of 100 mg/4ml or 200 mg/8 ml [1]. 
For the treatment of metastatic colorectal cancer (mCRC), patients receive 
aflibercept in combination with FOLFIRI treatment (consisting of 5-fluo-
rouracil, leucovorin and irinotecan) whereby aflibercept is to be administered 
prior to the FOLFIRI regimen as an intravenous infusion (4 mg/kg) over one 
hour every two weeks [1]. The FOLFIRI treatment consists of administra-
tion of irinotecan 180 mg/m2 intravenous infusion over 90 minutes, folinic 
acid (leucovorin) 400 mg/m2 intravenous over 2 hours, followed by 5-fluo-
rouracil 400 mg/m2 intravenous bolus and 5-fluorouracil 2,400 mg/m2 con-
tinuous intravenous infusion over 46 hours [3].This procedure should be re-
peated every two weeks until disease progression or unacceptable toxicity [3]. 
 
 
2 Indication 
Aflibercept (Zaltrap®) combined with FOLFIRI (5-fluorouracil/irinotecan/ 
leucovorin) treatment is indicated in adult patients with mCRC that is re-
sistant to or has progressed after an oxaliplatin-containing regimen [3].  
 
 
3 Current regulatory status 
Aflibercept (Zaltrap®) has been approved by the FDA for the treatment of 
mCRC that is resistant to or has progressed after an oxaliplatin-containing 
regimen, used in combination with FOLFIRI treatment in March 2012 [1]. 
In February 2013 the EMA granted marketing authorization for Zaltrap® for 
the same indication like the FDA in the European Union. 
For the treatment of wet macular degeneration the EMA approved aflibercept 
(Eylea®) in November 2012 [3]. 
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4 Burden of disease 
CRC develops in the tissues of the colon and/or rectum. It is the third most 
common cancer and the third leading cause of cancer-related mortality in men 
and women in the United States [4]. In Austria, CRC is the third most com-
mon malignancy diagnosed in men and the second most common malignancy 
diagnosed in women. In 2010, the incidence rate in Austria for both men and 
women was 28.1 (per 100,000 people per year), mortality rate was 11.9 (per 
100,000 people per year) [5]. 
Median age at diagnosis for cancer of the colon and rectum is about 69 years 
and the overall 5-year relative survival rate (for 2003-2009) is 64.9% [6]. 
Histologically, more than 95% of CRCs are adenocarcinomas. Less common 
types occurring are carcinoid tumors, gastrointestinal stromal tumors, lym-
phomas or sarcomas [7].  
Risk factors for CRC are increasing age, colorectal polyps, a family history 
of CRC and hereditary conditions (such as familial polyposis, hereditary 
nonpolyposis colon cancer, Lynch syndrome variants I and II, personal his-
tory of ulcerative colitis or Crohn colitis). Moreover, diet (high in fat, low in 
calcium, folate and fiber) and cigarette smoking do appear to increase the 
risk of developing colorectal cancer [4]. 
Common symptoms of CRC are bloody or tarry stool, abdominal pain, oth-
erwise unexplained iron deficiency anemia, a change in bowel habits, weak-
ness and/or weight loss. Symptoms manifest themselves usually at rather ad-
vanced stages of the disease due to tumor growth into the intestinal lumen. 
CRC is a potentially metastatic disease, the most frequently affected sites are 
the regional lymph nodes, liver, lungs, and peritoneum. Approximately 20% 
of patients have metastasis at the time CRC is diagnosed. For the staging of 
CRC the TNM classification (primary tumour -T, status of the regional nodes 
– N, distant metastasis -M) is applied [8].  
 
 
5 Current treatment 
An abundance of treatment options are available for CRC. Selection of ther-
apy depends on the site and extent of metastatic disease, performance status, 
organ function, comorbidity of the patient and KRAS mutation status [9].  
In general, patients who are able to tolerate it should receive chemotherapy 
doublets as first-line therapy. Oxaliplatin-based options for the first-line ther-
apy are, for example, FOLFOX (=fluorouracil, leucovorin, oxaliplatin) or 
CapeOX-based (capecitabine, oxaliplatin) regimens with or without bevaci-
zumab, FOLFOX ± panitumab for (KRAS wild-type gene only) or FOL-
FOXIRI (=fluorouracil plus leucovorin, oxaliplatin, and irinotecan).  
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In case of disease progression after these first-line therapies, treatment op-
tions will be selected according to the first-line regimen received and include 
[10, 11]: 
 FOLFIRI ± bevacizumab 
 FOLFIRI ± aflibercept 
 Irinotecan ± bevacizumab 
 Irinotecan ± aflibercept 
 Cetuximab or panitumumab (KRAS WT gene only) +irinotecan 
 Regorafenib (not yet licenced in the European Union). 
If bevacizumab has been administered in combination with first-line chemo-
therapy, continuation of bevacizumab with second-line fluoroyrimidine-based 
chemotherapy is a commonly used regimen [11].  
Alternatively, the first-line therapy can be started by using an irinotecan con-
taining regimen (FOLFIRI); in case of disease progression further treatment 
options would contain oxaliplatin-based regimens. 
 
 
6 Evidence 
To identify relevant literature, a literature search was conducted in April 2013 
in medical databases (Embase, Medline, CRD Database, The Cochrane Li-
brary). Search terms used were “Aflibercept”, “AVE0005”, “AVE 0005”, “Zal-
trap”, “eylea”, “vascular endothelial growth factor trap”, “vasculotropin trap” 
and “VEGF Trap” in combination with “Colorectal Neoplasms” (MeSH), 
“colorectal cancer”, “mCRC”, “(refractory or relapsed) near colorectal can-
cer”. Inclusion criteria were phase III study (full text articles, abstracts) and 
phase II studies (full text). Overall, 99 references were identified of which 
two were included in this report: 
 a phase III trial, evaluating the effect of adding aflibercept to FOL-
FIRI in patients with mCRC previously treated with an oxaliplatin –
based regimen [12]. 
and 
 a phase II study evaluating the safety and efficacy of aflibercept in 
pretreated patients with mCRC [13]. 
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6.1 Efficacy and safety – Phase III studies 
Table 1: Summary of efficacy 
Study title  
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan improves survival in a phase III 
randomized trial in patients with metastatic colorectal cancer previously treated with an Oxaliplatin-
based regimen [10]. 
Study  
identifier 
NCT00561470, EudraCT Number: 2007-000820-42, VELOUR trial 
Design Prospective, multinational, randomized, double-blind, parallel-arm 
Duration  Enrolment: November 2007 to March 2010 
Median follow-up: 22.28 months 
Cut-off dates for analyses: 2011-02-07  
Hypothesis Superiority 
Funding Sanofi (in collaboration with Regeneron Pharmaceuticals) 
Treatment 
groups 
Intervention 
(n=612) 
4 mg/kg Aflibercept IV over 1 hour every 2 weeks 
followed immediately by 
FOLFIRI (irinotecan 180 mg/m2 IV over 90 minutes, with 
leucovorin 400 mg/m2 over 2 hours, followed by fluorouracil 
400 mg/m2 bolus and fluorouracil 2400 mg/m2 continuous 
infusion over 46 hours) 
Patients received a median of seven cycles of aflibercept 
Control 
(n=614) 
Placebo  
and 
FOLFIRI (irinotecan 180 mg/m2 IV over 90 minutes, with leucovorin 
400 mg/m2 over 2 hours, followed by fluorouracil 400 mg/m2 bolus 
and fluorouracil 2400 mg/m2 continuous infusion over 46 hours 
Patients received a median of eight cycles of placebo 
Endpoints 
and 
definitions 
Overall survival  
(primary outcome) 
OS The time interval from randomization to death from 
any cause 
Progression-free 
survival 
PFS The interval from randomization to the first observation 
of disease progression (according to independent review 
committee review) or death from any cause 
Objective response OR Complete response and partial response 
Treatment-emergent 
adverse events 
– – 
Laboratory  
abnormalities 
– – 
Results and analysis 
Analysis  
description 
Intention-to-treat (ITT analysis) 
Primary Endpoint: overall survival, log rank test 
Response rate between control arm and aflibercept arm was compared using  
Cochrane-Mantel-Haenszel test. 
Analysis  
population 
Inclusion  Age (years) ≥ 18  
 Histologically or cytologically proven colorectal adenocarcinoma with 
metastatic disease not amenable to potentially curative treatment 
 Patients who experienced relapse within 6 months of completion 
of oxaliplatin—based adjuvant therapy 
 Prior administration of bevacizumab  
 ECOG performance status 0-2 
 Adverse events from prior anticancer therapy were to have 
recovered to grade ≤ 1 [NCI-CTCAE version 3.0] 
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Analysis  
population 
Exclusion  Known prior malignancies or known brain metastases, patients with 
adequately treated basal cell or squamous cell skin cancer, carcinoma 
in situ of the cervix, or any other cancer from which the patient 
had been disease-free for more than 5 years were permitted  
 Prior administration of irinotecan 
 Major surgery within 28 days 
 Uncontrolled hypertension within 3 months before enrolment 
 Deep vein thrombosis within 4 weeks before randomization 
 Pregnant and breast-feeding women 
Characteristics Median age (years): 61 (19-86) vs. 61 (21-82) 
Male (%): 57.5 vs. 59.6 
Prior bevacizumab (%): 30.5 vs. 30.4 
ECOG (%)0/1/2: 57.0/40.7/2.3 vs. 57.0/40.8/2.1 
Prior hypertension (%): 43.6 vs. 43.5 
Results Treatment group Placebo/FOLFIRI Aflibercept/FOLFIRI 
Number of subjects N = 614 N = 612 
Survival 
Median, months 
95.34% CI 
 
12.06 
11.072-13.109 
 
13.50 
12.517-14.949 
Survival probability, % 
12 months 
95.34 % CI 
18 months 
95.34% CI 
24 months 
95.34% CI 
30 months 
95.34% CI 
 
0.503 
0.462-0.543 
0.309 
0.269-0.348 
0.187 
0.149-0.225 
0.120 
0.080-0.160 
 
0.561 
0.521-0.602 
0.385 
0.343-0.427 
0.280 
0.237-0.324 
0.223 
0.178-0.268 
PFS 
median, months 
95% CI 
 
4.67 
4.21-5.36 
 
6.90 
6.51-7.2 
Best overall response, % 
Complete response 
Partial response 
Stable disease 
Response rate, % 
(complete response + 
partial response)  
95% CI 
 
0.4 
10.8 
64.9 
11.1 
 
 
8.5-13.8 
 
- 
19.8 
65.9 
19.8 
 
 
16.4-23.2 
Effect 
estimate per 
comparison 
Comparison groups  Intervention vs Control 
OS HR 0.817 
95.34% CI 0.713-0.937 
P value 0032 
PFS HR 0.758 
95% CI 0.661-0.869 
P value  < .0001 
Response rate  HR NR 
95% CI NR 
P value  < .001 
Abbreviations: OS= overall survival, PFS= progression-free survival, CI= confidence interval, HR= Hazard ratio, n= number, 
ECOG= Eastern Cooperative Oncology Group, NR= not reported 
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Table 2: Most frequent adverse events 
NCT00561470 
Adverse Event 
(according to NCI-CTCAE  
version 3.0)  
Placebo/FOLFIRI (n=605) Aflibercept/FOLFIRI (n=611) 
All Grades 
(%) 
Grade 
3 (%) 
Grade 
4 (%) 
All Grades 
(%) 
Grade 
3 (%) 
Grade 
4 (%) 
Any 97.9 45.1 17.4 99.2 62.0 21.4 
Diarrhea 56.5 7.6 0.2 69.2 19.0 0.3 
Asthenic conditions 50.2 10.4 0.2 60.4 16.0 0.8 
Stomatitis and ulceration 34.9 5.0 - 54.8 13.6 0.2 
Nausea 54 3.0 - 53.4 1.8 - 
Infections and infestations 32.7 6.1 0.8 46.2 11.0 1.3 
Hypertension 10.7 1.5 - 41.4 19.1 0.2 
Hemorrhage 
Epistaxis 
19 
7.4 
1.7 
- 
- 
- 
37.8 
27.7 
2.8 
0.2 
0.2 
- 
GI and abdominal pains 29.1 3.1 0.2 34 5.1 0.3 
Vomiting 33.4 3.5 - 32.9 2.6 0.2 
Decreased appetite 23.8 1.7 0.2 31.9 3.4 - 
Weight decreased 14.4 0.8 - 31.9 2.6 - 
Alopecia 30.1 - - 26.8 - - 
Dysphonia 3.3 - - 25.4 0.5 - 
Constipation 24.6 1.0 - 22.4 0.8 - 
Headache 8.8 0.3 - 22.3 1.6 - 
Palmar-plantar erythrodysesthesia 
syndrome 4.3 0.5 - 11.0 2.8 - 
Arterial thromboembolic event 1.5 0.5 - 2.6 0.8 1.0 
Venous thromboembolic event 7.3 2.6 3.6 9.3 3.1 4.7 
Fistula from GI origin 0.3 0.2 - 1.1 0.3 - 
Fistula from other than GI origin 0.2 - - 0.3 - - 
GI perforation 0.5 0.2 0.2 0.5 0.2 0.3 
Anemia 91.1 3.5 0.8 82.3 3.3 0.5 
Neutropenia 56.3 19.1 10.4 67.8 23.1 13.6 
Neutropenic complications 3.0 1.7 1.2 6.5 4.4 1.3 
Thrombocytopenia 33.8 0.8 0.8 47.4 1.7 1.7 
Proteinuria 40.7 1.2 - 62.2 7.5 0.3 
ALT increased 37.1 2.2 - 47.3 2.5 0.2 
Abbreviations: NCI= National Cancer Institute, CTCAE= Common Terminology Criteria of Adverse Events, GI= gastroin-
testinal, ALT=alanine transaminase 
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In this prospective, multinational, randomized, double-blind, parallel-arm 
phase III trial a total of 1,226 patients were included. The aim of the study 
was to evaluate the efficacy and safety of the combination of aflibercept plus 
FOLFIRI versus placebo plus FOLFIRI in patients with mCRC. All enrolled 
patients had disease progression with an oxaliplatin-based regimen. 
Patients were randomly assigned to either the FOLFIRI/aflibercept group 
(n=612) or to FOLFIRI/placebo group (n=614). Thus, patients received 4mg/ 
kg of aflibercept or placebo intravenously, followed subsequently by admin-
istration of the FOLFIRI (irinotecan, leucovorin and fluorouracil) regimen. 
Patients of FOLFIRI/aflibercept group received a median of nine cycles over-
all (with a median of seven cycles of aflibercept) versus eight cycles overall 
(median of eight cycles of placebo) in the FOLFIRI/placebo group. 30.5% of 
patients in the FOLFIRI/placebo arm and 30.4% of patients in the afliber-
cept/FOLFIRI arm received prior bevacizumab. 
The primary endpoint of the phase III trial was overall survival; secondary 
endpoints were progression-free survival, objective response, treatment emer-
gent adverse events and laboratory anomalies. Analyses after a median follow 
up time of 22.28 months showed that adding aflibercept to FOLFIRI led to a 
significantly improved median overall survival: median survival was 13.50 
versus 12.06 months in aflibercept/FOLFIRI versus placebo/FOLFIRI arm 
yielding a hazard ratio of 0.817 (95.34% CI, 0.713 to 0.937; P=.0032). Two-
year survival rates were 28.0% (aflibercept group) compared to 18.7% (con-
trol group).There was also a significant increase in median progression-free 
survival (6.9 months in the aflibercept group compared to 4.7 months in the 
control group). Response rate (complete response + partial response) was 19.8% 
in the aflibercept arm compared to 11.1% in the control arm. However, no 
patient in the aflibercept group and only 0.4% of patients in the control group 
achieved complete response. In contrast, 19.8% of patients in the aflibercept 
arm and 10.8% of patients in the control arm achieved partial response. 
In the context of the described phase III study, a subgroup analysis of the ef-
fects of prior bevacizumab use was conducted. The results indicated that 
adding aflibercept to FOLFIRI led to a consistent trend of increased overall 
survival and progression free survival, regardless of prior administration of 
bevacizumab. Furthermore, prior bevacizumab treatment did not appear to 
affect the safety profile of aflibercept [14]. 
In the aflibercept/FOLFIRI arm treatment-emergent adverse events occurred 
in 99.2% of patients and led to discontinuation from study treatment in 26.8% 
of patients. In comparison, 97.9% of control arm patients showed treatment-
emergent adverse events which led to treatment discontinuation in 12.1% of 
patients. There were more patients affected by adverse events of grade 3 and 
grade 4 in the aflibercept arm (83.5%) than in the control arm (62.5%), in 
particular hypertension, hemorrhage, arterial thromboembolic events and ve-
nous thromboembolic events were more frequent. A higher incidence in the 
aflibercept arm was also reported for diarrhea, asthenic conditions, stomatitis 
and ulceration, infections, palmar-plantar erythrodysesthesia, neutropenia 
and thrombocytopenia. The incidence of serious adverse events was 49% in 
the aflibercept group compared to 33% in the placebo group. Adverse events 
with a fatal outcome affected 13 patients in the aflibercept arm and 6 patients 
in the placebo arm. Adverse events, toxicity-related deaths, dose modifications 
and treatment-related withdrawals were also more frequent in the aflibercept 
arm [1]. Most common adverse events leading to study discontinuation were 
asthenic conditions, infections, diarrhea and hypertension. 
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6.2 Efficacy and safety – further studies 
An open-label, 2-stage, phase II clinical trial evaluated the safety and efficacy 
of aflibercept monotherapy in patients with mCRC pretreated with chemo-
therapy and/or EGFR inhibitors [13]. A total of 75 patients were assigned to 
either the bevacizumab-naive (n=24) or the prior bevacizumab cohort (n=51). 
Patients of both cohorts (n=74, one patient has been excluded due to ap-
pearance of brain metastasis) received 4 mg/kg intravenous aflibercept in two-
week cycles. 
The authors defined the endpoint as a combination of objective response rate 
and 16-week progression-free-survival. In the bevacizumab-naive cohort, 8 of 
24 patients (33.3%) achieved stable disease at 8 weeks and 5 of 24 patients 
(20.8%) achieved stable disease at ≥ 16 weeks. No cases of partial response 
were reported in this group. In the prior bevacizumab cohort, 21 of 50 pa-
tients (42.0%) obtained stable disease at 8 weeks and 6 of 50 patients (12.0%) 
achieved stable disease at ≥ 16 weeks. One patient in this group achieved a 
partial response. The median progression-free survival times were 2 months 
(95% CI: 1.7-8.6 months) in the bevacizumab-naive group and 2.4 months 
(95% CI: 1.9-3.7 months) in the prior bevacizumab cohort. Within this study, 
aflibercept did not show positive results in single-agents use. 
Median overall survival was 10.4 months (95% CI: 7.6-15.5) in the bevacizu-
mab-naive cohort vs. 8.5 months (95% CI: 6.2-10.6) in the prior bevacizumab 
cohort. Additionally the plasma levels for free and VEGF-bound aflibercept 
were analyzed: mean free to VEGF-bound aflibercept ratio was 1.82. This result 
suggests adequate availability of aflibercept to bind endogenous VEGF [13]. 
 
 
7 Estimated costs 
Aflibercept (Zaltrap®, 4mg/kg) is administered as an intravenous infusion 
over one hour every two weeks, in combination with FOLFIRI (5-fluorouracil, 
leucovorin and irinotecan) treatment. Aflibercept is available in single-use 
vials of 100 mg/4ml (25 mg/ml) or 200 mg/8ml (25 mg/ml) [1]. 
The costs for one cycle of aflibercept (assuming a body weight of 70kg) are 
estimated to range between € 1,245 (manufacturer´s price) [15] and € 1,358 
(Austrian health insurance) [16] resulting in monthly costs of € 2,490 and € 
2,714, respectively. In addition to that, costs for FOLFIRI treatment incur. 
According to manufacturer´s information, the estimated cycle number per 
patient is six [15], whereas a median of seven cycles were administered in 
the VELOUR trial. Applying these numbers would yield overall treatment 
costs between € 7,470 (manufacturer’s price) and € 8,142 (health insurance) 
for six cycles and between € 8,715 (manufacturer’s price) and € 9,506 (health 
insurance) for seven cycles. 
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8 Ongoing research 
A search in databases www.clinicaltrials.gov and www.clinicaltrialsregister.eu 
for trials concerning “metastatic colorectal cancer” and “aflibercept” was con-
ducted in May 2013 with the following results: 
 NCT01661270: the aim of this multinational, randomized, double-blind 
phase III study is to evaluate the improvement in progression-free sur-
vival of aflibercept versus placebo in patients with mCRC (treated with 
FOLFIRI after failure of an oxaliplatin-based regimen. The estimated 
study completion date is January 2016. 
 NCT01571284 (EudraCT Number: 2011-005724-17): a multicenter, sin-
gle-arm, open label phase III study to evaluate the safety and health-
related quality of life of aflibercept in patients with mCRC (previously 
treated with an oxaliplatin-containing regimen). The estimated study 
completion date is June 2015. 
 NCT01670721: a multicenter, single arm, open label, phase III study to 
assess the safety of aflibercept in patients with (mCRC) treated 
with irinotecan/5FU combination (FOLFIRI) after failure of an oxali-
platin-based regimen. Furthermore, this study aims to evaluate the 
health-related quality of life (HRQL) of aflibercept within the pa-
tient population. The estimated study completion date is June 2014. 
 NCT01754272: a non-interventional Follow-up study to the VELOUR 
trial (NCT00561470). The archived colorectal cancer and metastasized 
tissue tumor blocks of patients who have participated in the VELOUR 
trial will be analyzed. The aim of the study is to identify proteins or 
markers which represent individual response to treatment. The esti-
mated study completion date is December 2013.  
 NCT01646554: a randomized phase II/III study to evaluate the efficacy 
of FOLFOX alone versus FOLFOX and aflibercept in K-ras mutant 
in patients with resectable liver metastasis from CRC. The estimated 
study completion date is December 2016. 
Furthermore, several phase I and phase II studies were identified assessing 
single use of aflibercept or combined with capecitabine, OPTIMOX, FOL-
FIRI and modified FOLFOX6) in either pretreated or previously untreated 
patients.  
There are numerous partly ongoing, partly completed phase II and phase III 
studies evaluating the efficacy of aflibercept on further types of cancer in-
cluding metastatic thyroid cancer, ovarian cancer, metastatic non-small-cell 
lung cancer, advanced esophageal/gastric, metastatic pancreatic cancer or 
metastatic androgen-independent prostate cancer to name but a few. 
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9 Commentary 
Aflibercept (Zaltrap®) has been approved by both the EMA (in February 2013) 
and the FDA (in March 2012) in combination with FOLFIRI for the treat-
ment of mCRC after disease progression on an oxaliplatin-based treatment. 
The marketing authorization was based on the results of the above-mentioned 
phase III study (VELOUR trial), which showed significantly increased over-
all survival as well as progression-free survival [12]. In particular, median 
survival was 13.50 months versus 12.06 months in the aflibercept and the pla-
cebo group respectively, yielding a gain of 1.44 months (HR 0.817; 95.34% 
CI, 0.713-0.937; P=.0032). Median progression-free survival was 6.9 months 
in the aflibercept group and 4.7 months in the control group.  
These positive results are in contrast to the higher incidence of grade 3 and 
grade 4 adverse events reported in the aflibercept arm (83.5%) than in the 
control arm (62.5%). Also, serious adverse events occurred in 49% of patients 
in the aflibercept group compared to 33% in the placebo group. Adverse 
events with a fatal outcome affected 13 patients in the aflibercept arm and 6 
patients in the placebo arm. Adverse events, toxicity-related deaths, dose mod-
ifications and treatment-related withdrawals were also more frequent in the 
aflibercept arm [1]. 26.8% of patients receiving aflibercept and 12.1% receiv-
ing placebo discontinued from study treatment due to adverse events. 
Rather modest gains in overall survival and progression-free survival in ad-
dition to a higher number of adverse events, question if patients with this in-
curable disease will actually benefit from combining FOLFIRI with afliber-
cept, foremost since studies evaluating quality-of-life are still missing. Even 
though a study evaluating safety and health related quality-of-life of afliber-
cept in combination with FOLFIRI (NCT01670721) is currently recruiting 
patients, results will not be available before June 2014. Moreover, these re-
sults are achieved at monthly costs of € 2,716 (for two cycles), cost arising in 
addition to expenses for FOLFIRI treatment, premedication and treatment 
of side effects.  
Further, instead of comparing FOLFIRI + aflibercept to FOLFIRI + place-
bo, the combination with bevacizumab would have been a more meaningful 
comparator, thus, gains achieved in efficacy outcomes are further questioned. 
Similarly, only 30.4% of patients (aflibercept-arm) had previously been treat-
ed with bevacizumab, a therapy commonly administered as first-line therapy 
for mCRC. Even though results of a subgroup analysis yielded no statistical-
ly significant difference between patients previously treated with bevacizu-
mab and patients without prior bevacizumab therapy, the findings indicate 
that previously treated patients may benefit less from aflibercept [1].  
As already mentioned, the use of bevacizumab is a standard treatment op-
tion for the second line therapy of mCRC. Safety profiles of aflibercept and 
bevacizumab seem to be rather consistent, with the exception of hyperten-
sion and proteinuria which are more frequent in the aflibercept arm [1]. 
However, a detailed comparison of aflibercept and bevacizumab is not pos-
sible as long as direct comparative studies are missing. Also treatment selec-
tion based on costs proves difficult since the monthly costs for bevacizumab 
range, depending on the regimen used, between € 2,400 (7.5 mg/kg every 3 
weeks) and € 5,580 (10mg/kg every 2 weeks) in comparison to about € 2,700 
for aflibercept [16].  
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In summary, it can be stated that the positive effects of aflibercept regarding 
increased overall survival and progression-free survival are to be balanced 
against the high incidence of adverse events. Currently there are no data avail-
able concerning aflibercept and quality-of-life, results of an ongoing study 
may give more information about this essential parameter.  
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